Epithelial-mesenchymal transition enhances response to oncolytic herpesviral therapy through nectin-1

Human Gene Therapy

Volumn 25, Issue 6, 2014, Pages 539-551

  Chen, Chun Hao ^a   Chen, Wei Yi ^b   Lin, Shu Fu ^a,c   Wong, Richard J ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b ROCKEFELLER UNIVERSITY   (United States)

^c CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

GREEN FLUORESCENT PROTEIN; NECTIN 1; ONCOLYTIC HERPES VIRUS; SHORT HAIRPIN RNA; TRANSFORMING GROWTH FACTOR BETA; UVOMORULIN; CADHERIN; CDH1 PROTEIN, HUMAN; CELL ADHESION MOLECULE; NECTINS; ONCOLYTIC VIRUS;

ADENOCARCINOMA CELL LINE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL JUNCTION; CELL PROLIFERATION; CELL SURFACE; CELL VIABILITY ASSAY; CYTOTOXICITY; DRUG SENSITIVITY; EPITHELIAL MESENCHYMAL TRANSITION; FLUORESCENCE MICROSCOPY; GENE EXPRESSION; GENE SILENCING; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PANCREAS ADENOCARCINOMA; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RECEPTOR BLOCKING; THYROID FOLLICULAR CARCINOMA; TREATMENT RESPONSE; TUMOR REGRESSION; TUMOR VOLUME; VIRUS ATTACHMENT; VIRUS ENTRY; VIRUS REPLICATION; ANIMAL; BIOSYNTHESIS; CANCER TRANSPLANTATION; CELL MEMBRANE; GENETICS; METABOLISM; NEOPLASMS; PHYSIOLOGY; TUMOR CELL LINE; VIROLOGY;

ANIMALS; CADHERINS; CELL ADHESION MOLECULES; CELL LINE, TUMOR; CELL MEMBRANE; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION; HERPESVIRUS 1, HUMAN; HUMANS; MICE; NEOPLASM TRANSPLANTATION; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; TUMOR BURDEN; VIRUS ATTACHMENT; VIRUS INTERNALIZATION; VIRUS REPLICATION;

EID: 84902969251     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2013.177     Document Type: Article

References (55)

1. Anders, M., Christian, C., McMahon, M., et al. (2003). Inhibition of the Raf/MEK/ERK pathway up-regulates expression of the coxsackievirus and adenovirus receptor in cancer cells. Cancer Res. 63, 2088-2095. (Pubitemid 36538611)
2. Bennett, J.J., Malhotra, S., Wong, R.J., et al. (2001). Interleukin 12 secretion enhances antitumor efficacy of oncolytic herpes simplex viral therapy for colorectal cancer. Ann. Surg. 233, 819-826. (Pubitemid 32494563)
3. Coukos, G., Makrigiannakis, A., Kang, E.H., et al. (2000). Oncolytic herpes simplex virus-1 lacking ICP34.5 induces p53-independent death and is efficacious against chemotherapyresistant ovarian cancer. Clin. Cancer Res. 6, 3342-3353. (Pubitemid 30637766)
4. Eisenberg, D.P., Adusumilli, P.S., Hendershott, K.J., et al. (2005). 5-Fluorouracil and gemcitabine potentiate the efficacy of oncolytic herpes viral gene therapy in the treatment of pancreatic cancer. J. Gastrointest. Surg. 9, 1068-1077; discussion 1077-1069.
5. Ellenrieder, V., Hendler, S.F., Boeck, W., et al. (2001). Transforming growth factor β1 treatment leads to an epithelial- mesenchymal transdifferentiation of pancreatic cancer cells requiring extracellular signal-regulated kinase 2 activation. Cancer Res. 61, 4222-4228. (Pubitemid 32720992)
6. Farassati, F., Yang, A.D., and Lee, P.W. (2001). Oncogenes in Ras signalling pathway dictate host-cell permissiveness to herpes simplex virus 1. Nat. Cell Biol. 3, 745-750. (Pubitemid 32734253)
7. Fidler, I.J. (2003). The pathogenesis of cancer metastasis: The ''seed and soil'' hypothesis revisited. Nat. Rev. Cancer 3, 453-458. (Pubitemid 37328849)
8. Floor, S., van Staveren, W.C., Larsimont, D., et al. (2011). Cancer cells in epithelial-to-mesenchymal transition and tumor-propagating-cancer stem cells: Distinct, overlapping or same populations. Oncogene 30, 4609-4621.
9. Geraghty, R.J., Krummenacher, C., Cohen, G.H., et al. (1998). Entry of alphaherpesviruses mediated by poliovirus receptorrelated protein 1 and poliovirus receptor. Science 280, 1618- 1620. (Pubitemid 28277708)
10. Gil, Z., Rein, A., Brader, P., et al. (2007). Nerve-sparing therapy with oncolytic herpes virus for cancers with neural invasion. Clin. Cancer Res. 13, 6479-6485. (Pubitemid 350075038)
11. Huang, Y.Y., Yu, Z., Lin, S.F., et al. (2007). Nectin-1 is a marker of thyroid cancer sensitivity to herpes oncolytic therapy. J. Clin. Endocrinol. Metab. 92, 1965-1970. (Pubitemid 46997218)
12. Hugo, H., Ackland, M.L., Blick, T., et al. (2007). Epithelial- mesenchymal and mesenchymal-epithelial transitions in carcinoma progression. J. Cell. Physiol. 213, 374-383. (Pubitemid 47509716)
13. Jensen, K., Patel, A., Larin, A., et al. (2010). Human herpes simplex viruses in benign and malignant thyroid tumours. J. Pathol. 221, 193-200.
14. Kalluri, R., and Weinberg, R.A. (2009). The basics of epithelial- mesenchymal transition. J. Clin. Invest. 119, 1420-1428.
15. [Published erratum appears in J. Clin. Invest. 2010;120:1786.]
16. Kooby, D.A., Carew, J.F., Halterman, M.W., et al. (1999). Oncolytic viral therapy for human colorectal cancer and liver metastases using a multi-mutated herpes simplex virus type-1 (G207). FASEB J. 13, 1325-1334. (Pubitemid 29382501)
17. Krummenacher, C., Baribaud, F., Ponce de Leon, M., et al. (2004). Comparative usage of herpesvirus entry mediator A and nectin-1 by laboratory strains and clinical isolates of herpes simplex virus. Virology 322, 286-299. (Pubitemid 38521143)
18. Kurrey, N.K., Jalgaonkar, S.P., Joglekar, A.V., et al. (2009). Snail and slug mediate radioresistance and chemoresistance by antagonizing p53-mediated apoptosis and acquiring a stem-like phenotype in ovarian cancer cells. Stem Cells 27, 2059-2068.
19. La Boissiere, S., Izeta, A., Malcomber, S., and O'Hare, P. (2004). Compartmentalization of VP16 in cells infected with recombinant herpes simplex virus expressing VP16-green fluorescent protein fusion proteins. J. Virol. 78, 8002-8014. (Pubitemid 38944285)
20. Lacher, M.D., Tiirikainen, M.I., Saunier, E.F., et al. (2006). Transforming growth factor-β receptor inhibition enhances adenoviral infectability of carcinoma cells via up-regulation of coxsackie and adenovirus receptor in conjunction with reversal of epithelial-mesenchymal transition. Cancer Res. 66, 1648-1657. (Pubitemid 43259949)
21. Lin, S.F., Price, D.L., Chen, C.H., et al. (2008). Oncolytic vaccinia virotherapy of anaplastic thyroid cancer in vivo. J. Clin. Endocrinol. Metab. 93, 4403-4407. (Pubitemid 352789538)
22. McAuliffe, P.F., Jarnagin, W.R., Johnson, P., et al. (2000). Effective treatment of pancreatic tumors with two multimutated herpes simplex oncolytic viruses. J. Gastrointest. Surg. 4, 580-588.
23. Mineta, T., Rabkin, S.D., Yazaki, T., et al. (1995). Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat. Med. 1, 938-943.
24. Montgomery, R.I., Warner, M.S., Lum, B.J., and Spear, P.G. (1996). Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family. Cell 87, 427-436. (Pubitemid 26374317)
25. Onder, T.T., Gupta, P.B., Mani, S.A., et al. (2008). Loss of Ecadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Res. 68, 3645-3654.
26. Peng, K.W., TenEyck, C.J., Galanis, E., et al. (2002). Intraperitoneal therapy of ovarian cancer using an engineered measles virus. Cancer Res. 62, 4656-4662.
27. Perez-Moreno, M., Jamora, C., and Fuchs, E. (2003). Sticky business: Orchestrating cellular signals at adherens junctions. Cell 112, 535-548. (Pubitemid 36263085)
28. Polyak, K., and Weinberg, R.A. (2009). Transitions between epithelial and mesenchymal states: Acquisition of malignant and stem cell traits. Nat. Rev. Cancer 9, 265-273.
29. Reid, V., Yu, Z., Schuman, T., et al. (2008). Herpes oncolytic therapy of salivary gland carcinomas. Int. J. Cancer 122, 202- 208. (Pubitemid 350209997)
30. Roussos, E.T., Keckesova, Z., Haley, J.D., et al. (2010). AACR special conference on epithelial-mesenchymal transition and cancer progression and treatment. Cancer Res. 70, 7360- 7364.
31. Shah, A.N., Summy, J.M., Zhang, J., et al. (2007). Development and characterization of gemcitabine-resistant pancreatic tumor cells. Ann. Surg. Oncol. 14, 3629-3637. (Pubitemid 350160137)
32. 134.5 mutants of herpes simplex virus 1. J. Virol. 80, 1110-1120. (Pubitemid 43134068)
33. Spear, P.G., and Longnecker, R. (2003). Herpesvirus entry: An update. J. Virol. 77, 10179-10185. (Pubitemid 37129662)
34. Stanziale, S.F., Petrowsky, H., Adusumilli, P.S., et al. (2004). Infection with oncolytic herpes simplex virus-1 induces apoptosis in neighboring human cancer cells: A potential target to increase anticancer activity. Clin. Cancer Res. 10, 3225- 3232. (Pubitemid 38619704)
35. Stewart, S.A., Dykxhoorn, D.M. Palliser, D., et al. (2003). Lentivirus-delivered stable gene silencing by RNAi in primary cells. RNA 9, 493-501. (Pubitemid 36356735)
36. Takai, Y., Irie, K., Shimizu, K., et al. (2003). Nectins and nectin-like molecules: Roles in cell adhesion, migration, and polarization. Cancer Sci. 94, 655-667. (Pubitemid 37160921)
37. Thiery, J.P., Acloque, H., Huang, R.Y., and Nieto, M.A. (2009). Epithelial-mesenchymal transitions in development and disease. Cell 139, 871-890.
38. Thompson, E.W., Newgreen, D.F., and Tarin, D. (2005). Carcinoma invasion and metastasis: A role for epithelial- mesenchymal transition? Cancer Res. 65, 5991-5995; discussion 5995.
39. Toda, M., Rabkin, S.D., and Martuza, R.L. (1998). Treatment of human breast cancer in a brain metastatic model by G207, a replication-competent multimutated herpes simplex virus 1. Hum. Gene Ther. 9, 2177-2185. (Pubitemid 28498004)
40. Toyoizumi, T., Mick, R., Abbas, A.E., et al. (1999). Combined therapy with chemotherapeutic agents and herpes simplex virus type 1 ICP34.5 mutant (HSV-1716) in human non-small cell lung cancer. Hum. Gene Ther. 10, 3013- 3029.
41. Walker, J.R., McGeagh, K.G., Sundaresan, P., et al. (1999). Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207. Hum. Gene Ther. 10, 2237-2243. (Pubitemid 29416302)
42. Wang, P.Y., Currier, M.A., Hansford, L., et al. (2012). Expression of HSV-1 receptors in EBV-associated lymphoproliferative disease determines susceptibility to oncolytic HSV. Gene Ther. 20, 761-769.
43. Wong, J., Kelly, K., Mittra, A., et al. (2010). A third-generation herpesvirus is effective against gastroesophageal cancer. J. Surg. Res. 163, 214-220.
44. Wong, R.J., Kim, S.H., Joe, J.K., et al. (2001a). Effective treatment of head and neck squamous cell carcinoma by an oncolytic herpes simplex virus. J. Am. Coll. Surg. 193, 12-21. (Pubitemid 32591620)
45. Wong, R.J., Patel, S.G., Kim, S., et al. (2001b). Cytokine gene transfer enhances herpes oncolytic therapy in murine squamous cell carcinoma. Hum. Gene Ther. 12, 253-265. (Pubitemid 32163897)
46. Wong, R.J., Joe, J.K., Kim, S.H., et al. (2002). Oncolytic herpesvirus effectively treats murine squamous cell carcinoma and spreads by natural lymphatics to treat sites of lymphatic metastases. Hum. Gene Ther. 13, 1213-1223. (Pubitemid 34746701)
47. Wong, R.J., Chan, M.K., Yu, Z., et al. (2004). Effective intravenous therapy of murine pulmonary metastases with an oncolytic herpes virus expressing interleukin 12. Clin. Cancer Res. 10, 251-259. (Pubitemid 38114187)
48. Yang, A.D., Fan, F., Camp, E.R., et al. (2006). Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines. Clin. Cancer Res. 12, 4147-4153.
49. Yang, J., and Weinberg, R.A. (2008). Epithelial-mesenchymal transition: At the crossroads of development and tumor metastasis. Dev. Cell 14, 818-829. (Pubitemid 351757205)
50. Yoon, M., and Spear, P.G. (2002). Disruption of adherens junctions liberates nectin-1 to serve as receptor for herpes simplex virus and pseudorabies virus entry. J. Virol. 76, 7203-7208.
51. Yu, Z., Eisenberg, D.P., Singh, B., et al. (2004). Treatment of aggressive thyroid cancer with an oncolytic herpes virus. Int. J. Cancer 112, 525-532. (Pubitemid 39390620)
52. Yu, Z., Chan, M.K., O-charoenrat, P., et al. (2005). Enhanced nectin-1 expression and herpes oncolytic sensitivity in highly migratory and invasive carcinoma. Clin. Cancer Res. 11, 4889-4897.
53. Yu, Z., Adusumilli, P.S., Eisenberg, D.P., et al. (2007a). Nectin- 1 expression by squamous cell carcinoma is a predictor of herpes oncolytic sensitivity. Mol. Ther. 15, 103-113. (Pubitemid 46043655)
54. Yu, Z., Li, S., Huang, Y.Y., et al. (2007b). Calcium depletion enhances nectin-1 expression and herpes oncolytic therapy of squamous cell carcinoma. Cancer Gene Ther. 14, 738-747. (Pubitemid 47080363)
55. Yu, Z., Li, S., Huang, Y.Y., et al. (2008). Sensitivity of squamous cell carcinoma lymph node metastases to herpes oncolytic therapy. Clin. Cancer Res. 14, 1897-1904. (Pubitemid 351469477)